Widespread use of human induced pluripotent stem cell (hiPSC) derived mature cell types is restricted by complex differentiation protocols and inefficient reprogramming methods. By applying a novel gene engineering approach, opti-oxTM, to cellular reprogramming these restrictions have been largely overcome. This proprietary technology enables precise reprogramming and homogeneous differentiation of entire stem cell cultures into any desired cell type.
IMI launches €45m call for coronavirus emergency
Latest NewsThe Innovative Medicines Initiative (IMI) has announced a €45m funding for the development of therapeutics and diagnostics to tackle coronavirus outbreaks.
Immunocore Ltd raises US$130m in Series B round
Latest NewsWith the financing led by General Atlantic, the British company wants to expand a novel platform and advance its ImmTAX pipeline to the clinic.
Nouscom: Made official
AppointmentsShe was already serving as interim CEO since Nouscom founder Alfredo Nicosia retired in May 2019. Now, Marina Udiers appointment at the Basel-based immuno-oncology company has been made permanent.
Vitamin C may boost checkpoint inhibitor efficacy
Latest NewsHigh amounts of injected vitamin C may delay the growth of many types of tumours and boost the anticancer power of immune checkpoint therapies, report Italian oncologists.
Roche grabs Bicycle Therapeutics’ platform
Latest NewsRoche AGs has paid US$30m upfront in a potential US$1.7bn deal to get access to Bicycle Therapeutics plc’s technology platform to target immune checkpoints.
Human iPSC derived neurons for research and HTS
ProductsWidespread use of human induced pluripotent stem cell (hiPSC) derived mature cell types is restricted by complex differentiation protocols and inefficient reprogramming methods. By applying a novel gene engineering approach, opti-oxTM, to cellular reprogramming these restrictions have been largely overcome. This proprietary technology enables precise reprogramming and homogeneous differentiation of entire stem cell cultures into any desired cell type.
Microglia inhibitor stops neuronal cell death after TBI
Latest NewsPost-Brexit budget drives cuts in Horizon Europe
Latest NewsNegotiations of the EU Council on the EU’s seven-year budget have failed, putting R&D funding at risk for significant cuts.
Royal DSM acquires Glycom A/S for €765m
Latest NewsRoyal DSM NV has entered the growing market of human milk oligosaccharides (HMO) taking over the producer of recombinant 2′-fucosyl lactose, Danish Glycom A/S.
Immatics Biotechnologies lands €1.1bn deal with GSK
Latest NewsUS-German immunooncology specialist Immatics Biotechnologies GmbH has licensed two of its TCR-T programs to GlaxoSmithKline for US$50m upfront.